Clinical Trials · NCT06382948
Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i.
- Phase
- Phase 3
- Recruitment status
- Recruiting
- Sponsor
- MedSIR
- Enrollment
- 240
- Start date
- Dec 2024
- Locations
- 99 sites, 9 countries
- Primary endpoint
- To demonstrate superiority of elacestrant+everolimus vs. elacestrant+placebo in prolonging PFS based on a BIRC in patients with ER[+]/HER2[-], ESR1-mutated, ABC that have previously received ET+CDK4/6i (all patients).